395 related articles for article (PubMed ID: 31369184)
1. Immune responses against enterovirus A71 infection: Implications for vaccine success.
Aw-Yong KL; NikNadia NMN; Tan CW; Sam IC; Chan YF
Rev Med Virol; 2019 Sep; 29(5):e2073. PubMed ID: 31369184
[TBL] [Abstract][Full Text] [Related]
2. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
3. Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
Zhang C; Wang Y; Ma S; Li L; Chen L; Yan H; Peng T
Viral Immunol; 2016 Jun; 29(5):288-95. PubMed ID: 27259043
[TBL] [Abstract][Full Text] [Related]
4. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Mao Q; Wang Y; Bian L; Xu M; Liang Z
Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
[TBL] [Abstract][Full Text] [Related]
5. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
6. Mapping Enterovirus A71 Antigenic Determinants from Viral Evolution.
Huang SW; Tai CH; Fonville JM; Lin CH; Wang SM; Liu CC; Su IJ; Smith DJ; Wang JR
J Virol; 2015 Nov; 89(22):11500-6. PubMed ID: 26339057
[TBL] [Abstract][Full Text] [Related]
7. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.
Jiang H; Zhang Z; Rao Q; Wang X; Wang M; Du T; Tang J; Long S; Zhang J; Luo J; Pan Y; Chen J; Ma J; Liu X; Fan M; Zhang T; Sun Q
Emerg Microbes Infect; 2021 Dec; 10(1):619-628. PubMed ID: 33682641
[TBL] [Abstract][Full Text] [Related]
8. Enterovirus A71 Infection Activates Human Immune Responses and Induces Pathological Changes in Humanized Mice.
Ke Y; Liu WN; Her Z; Liu M; Tan SY; Tan YW; Chan XY; Fan Y; Huang EK; Chen H; En Chang KT; Chan JKY; Hann Chu JJ; Chen Q
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429352
[TBL] [Abstract][Full Text] [Related]
9. A Polysaccharide Purified From
Lin YL; Shih C; Cheng PY; Chin CL; Liou AT; Lee PY; Chiang BL
Front Immunol; 2020; 11():561758. PubMed ID: 33117346
[TBL] [Abstract][Full Text] [Related]
10. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development.
Yee PTI; Laa Poh C
Virology; 2017 Jun; 506():121-129. PubMed ID: 28384566
[TBL] [Abstract][Full Text] [Related]
12. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development.
Chang YK; Chen KH; Chen KT
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e70. PubMed ID: 30427405
[TBL] [Abstract][Full Text] [Related]
13. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
14. VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.
Hsieh W-S; Chao C-H; Shen C-Y; Cheng D; Huang S-W; Wang Y-F; Chen C-C; Chen S-H; Hsu L-J; Wang J-R
J Virol; 2024 Jan; 98(1):e0155823. PubMed ID: 38174926
[TBL] [Abstract][Full Text] [Related]
15. Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice.
Chang J; Li J; Liu X; Liu G; Yang J; Wei W; Zhang W; Yu XF
BMC Microbiol; 2015 Jul; 15():139. PubMed ID: 26169371
[TBL] [Abstract][Full Text] [Related]
16. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
17. Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients.
Aw-Yong KL; Sam IC; Koh MT; Chan YF
PLoS One; 2016; 11(11):e0165659. PubMed ID: 27806091
[TBL] [Abstract][Full Text] [Related]
18. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
19. Interplays between Enterovirus A71 and the innate immune system.
Chen KR; Ling P
J Biomed Sci; 2019 Dec; 26(1):95. PubMed ID: 31787104
[TBL] [Abstract][Full Text] [Related]
20. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study.
Wei X; Yang J; Gao L; Wang L; Liao Q; Qiu Q; Luo K; Yu S; Zhou Y; Liu F; Chen Q; Zhang J; Dai B; Yang H; Zhou J; Xing W; Chen X; He M; Ren L; Guo J; Luo L; Wu P; Chen Z; van Doorn HR; Cauchemez S; Cowling BJ; Yu H
Lancet Infect Dis; 2021 Mar; 21(3):418-426. PubMed ID: 33031750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
